More bad news for Prempro
Executive Summary
Preliminary analysis from the Women's Health Initiative Memory Study evaluating the use of estrogen plus progestin on the development of dementia and mild cognitive impairment suggests negative results. "In contrast to previous work that suggested a beneficial effect on memory and cognition, the preliminary analyses of this arm of WHIMS suggest certain negative findings in a small percentage of the study participants," Wyeth said. An earlier National Institutes of Health-funded study found Wyeth's Premarin (conjugated estrogens) had no effect in the treatment of Alzheimer's disease (1"The Pink Sheet" Feb. 8, 2000, p. 8)...
You may also be interested in...
Premarin Alzheimer's Prevention Studies Urged; Treatment Trial Negative
A trial finding no effect for Premarin in the treatment of Alzheimer's does not rule out a role for estrogen replacement therapy in prevention of the disease, Wyeth-Ayerst and the study authors pointed out.
Pink Sheet Podcast: Woodcock To Be Acting US FDA Chief, Key Staff Depart, Political Donations Shift
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.
Liquid Biopsy Company Delfi Diagnostics Raised $100M For New Class of Early Cancer Detection Test
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: